NCT02973724

EC95 of Remifentanil for Preventing Cough

Predicted EC95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Ajou University School of Medicine · Academic / Other
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

Detailed description

At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Conditions

• Drug Usage

Interventions

Type	Name	Description
DRUG	Remifentanil	The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
DRUG	Propofol anesthesia	Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2016-11-25
• Last updated: 2017-06-09

Locations

1 site across 1 country: South Korea